Premarket Analysis: SCNX - Scienture Holdings Breakout NewsPurchased shares of SCNX at $2.89 after the company had a breakout, releasing news of partnering with Kindeva to launch the 10mg Rezenopy nasal spray for opioid overdose treatment. We're looking for a $4.92 retest, entering with a $2.22 stop loss on the Trade.
FINANCIAL NEWS:
7:41 AM EST, March 0